Portfolio company R3 Vascular expanded its management team with two senior executives.
R3 Vascular develops bioresorbable scaffolds that rival metal drug eluting stents, utilizing a unique polymer and proprietary technologies for treating peripheral arterial disease (PAD)
R3 Vascular develops bioresorbable scaffolds that rival metal drug eluting stents, utilizing a unique polymer and proprietary technologies for treating peripheral arterial disease (PAD).